All In Biotech

Investigational drug · Phase 2

UCART22

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for B-cell Acute Lymphoblastic Leukemia.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "UCART22"

First trial start

2019

Oct 14, 2019

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "UCART22", any sponsor or status.

Conditions studied

As listed on its trial records.

  • B-cell Acute Lymphoblastic Leukemia

Approved drugs for the same conditions: Acute lymphoblastic leukemia · Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "UCART22" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for B-cell Acute Lymphoblastic Leukemia

  • MK-2140Zilovertamab Vedotin, VLS-101Phase 39 trials

    Merck & Co. · Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia

  • MK-1045CN-201Phase 36 trials

    Merck & Co. · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular

  • single CNCT19Phase 23 trials

    Juventas Cell Therapy Ltd. · Relapsed or Refractory Acute Lymphoblastic Leukemia, B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma

  • YK012Phase 22 trials

    Excyte Biopharma Ltd · Systemic Lupus Erythematosus (SLE), B-cell Acute Lymphoblastic Leukemia

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.